| A gain-of-function mutation of JAK2 in myeloproliferative disorders R Kralovics, F Passamonti, AS Buser, SS Teo, R Tiedt, JR Passweg, ... New England Journal of Medicine 352 (17), 1779-1790, 2005 | 4673 | 2005 |
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ... Blood, The Journal of the American Society of Hematology 113 (13), 2895-2901, 2009 | 1512 | 2009 |
| Efficacy and safety of low-dose aspirin in polycythemia vera R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ... New England Journal of Medicine 350 (2), 114-124, 2004 | 1302 | 2004 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1258 | 2022 |
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and … N Gangat, D Caramazza, R Vaidya, G George, K Begna, S Schwager, ... Journal of Clinical Oncology 29 (4), 392-397, 2011 | 1211 | 2011 |
| Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ... Journal of Clinical Oncology 23 (30), 7594-7603, 2005 | 1129 | 2005 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010 | 1086 | 2010 |
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ... Journal of clinical oncology 29 (6), 761-770, 2011 | 1045 | 2011 |
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ... New England Journal of Medicine 372 (5), 426-435, 2015 | 992 | 2015 |
| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... New England Journal of Medicine 368 (1), 22-33, 2013 | 946 | 2013 |
| Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA … MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ... Blood, The Journal of the American Society of Hematology 96 (4), 1247-1253, 2000 | 819 | 2000 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 814 | 2013 |
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons A Tefferi, TL Lasho, CM Finke, RA Knudson, R Ketterling, CH Hanson, ... Leukemia 28 (7), 1472-1477, 2014 | 700 | 2014 |
| Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ... Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012 | 667 | 2012 |
| Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ... The American journal of medicine 117 (10), 755-761, 2004 | 630 | 2004 |
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ... Journal of clinical oncology 29 (23), 3179-3184, 2011 | 584 | 2011 |
| Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet T Barbui, A Tefferi, AM Vannucchi, F Passamonti, RT Silver, R Hoffman, ... Leukemia 32 (5), 1057-1069, 2018 | 563 | 2018 |
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for … G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ... Leukemia 22 (2), 437-438, 2008 | 560 | 2008 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 557 | 2020 |
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among … RM Emanuel, AC Dueck, HL Geyer, JJ Kiladjian, S Slot, S Zweegman, ... Journal of clinical oncology 30 (33), 4098-4103, 2012 | 521 | 2012 |
